CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, September 24, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval in the United Kingdom for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin, and etoposide.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

Press Release

The United Kingdom approves Zepzelca® (lurbinectedin) by PharmaMar in combination with atezolizumab for first-line maintenance treatment of small cell lung cancer

- **With this new approval, the treatment is now already available in 21 territories.**

Madrid, September 24th, 2026.- PharmaMar (MSE: PHM) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval in the United Kingdom for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin, and etoposide.

This approval is based on the results of the Phase III IMforte trial.[1]

According to the National Lung Cancer Audit (NLCA), 37,750 people were diagnosed with lung cancer in England only in 2023. Since small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases, this would correspond to roughly to 5,700 SCLC cases annually[2].

With this authorization, the United Kingdom joins the list of the territories where this combination has been approved, bringing the total number to 21, including the European Union (EU) and the United States.

[1] Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial - The Lancet

[2] National Cancer Audit Collaborating Centre (NATCAN). National Lung Cancer Audit State of the Nation 2025: An audit of care received by people diagnosed with lung cancer in England and Wales during 2023. London: Royal College of Surgeons of England; 2025.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself. In addition, Zepzelca® (lurbinectedin), in the US and other countries; and Aplidin® (plitidepsin), in Australia, each with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: PM534 and PM54.

Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi) and contract-manufacturing (CDMO) of oligonucleotides. For more information, please visit: www.pharmamar.com .

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

Media Contact:
Lara Vadillo – Communications director lvadillo@pharmamar.com
Phone: +34 918466000

Capital Markets & Investor Relations:
José Luis Moreno– VP Capital Markets & Investor Relations
Natalia Amo – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at **www.pharmamar.com**